Monday, October 08, 2018 1:28:19 PM
I would like to know more about the FOXP3 densities and proximities to CD8 observed. In case you haven't noticed, I am a firm believer that CTLA-4 on the FOXP3 Tregs are preventing T cell activation.
Would TAVO be more successful if it could be expressed more productively in the TME or TDL? Is tissue heterogeneity preventing adequate expression of IL-12? Would improvements to the plasmid construct lead to better expression, thus improvements in NK cell activation/expansion and FLT3L production? If so, then a program solely focused on improving IL-12 expression would make complete sense.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM